(www.cnbc.com)

Show context

snowwrestler ◴[16 Nov 25 23:39 UTC] No.45949515[source]▶

It doesn’t matter if it is a sustainable business. People will do what they can to maximize their income now. If 10 companies are withholding a cure to milk the patients, any one of them can break from that strategy at any time, with near-instant financial reward and competitive advantage. It is not a stable equilibrium.

replies(3): >>45949532 #>>45949904 #>>45953315 #

1. idontwantthis ◴[16 Nov 25 23:41 UTC] No.45949532[source]▶

>>45949515 #

As long as government regulation prevents them from forming a cartel.

replies(3): >>45949579 #>>45950574 #>>45955111 #

2. AuthAuth ◴[16 Nov 25 23:48 UTC] No.45949579[source]▶

>>45949532 (TP) #

It shouldnt be limited to companies within the country. Any foreign company can be a market disruptor here. Assuming the drug approval admin isnt working alongside the 'cartel'.

replies(2): >>45949918 #>>45950845 #

3. zdc1 ◴[17 Nov 25 00:48 UTC] No.45949918[source]▶

>>45949579 #

And then there's medical tourism, for the people who prefer to shop at one of the other 'cartels'

4. snowwrestler ◴[17 Nov 25 03:15 UTC] No.45950574[source]▶

>>45949532 (TP) #

Ah yes, the cartel, a famously stable arrangement that never ends in cheating or betrayal.

5. ComplexSystems ◴[17 Nov 25 04:27 UTC] No.45950845[source]▶

>>45949579 #

And only in the very particular scenario of a national-only cartel which has not successfully roped in other international pharma companies.

6. thrance ◴[17 Nov 25 16:28 UTC] No.45955111[source]▶

>>45949532 (TP) #

And as long as those cartels aren't powerful enough to buy the government into submission.

↑

Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)